SEMAX
Semax is a nootropic and neuroprotective peptide originally developed in Russia. Research has explored its effects on memory, attention and neurological recovery, with particular interest in its influence on brain plasticity and BDNF signalling.
SEMAX — QUICK SUMMARY
What is Semax?
Semax is a synthetic peptide derived from a short fragment of adrenocorticotropic hormone (ACTH). Unlike ACTH itself, Semax is primarily studied for its effects on the brain rather than for stimulating adrenal hormone production.
It was originally developed in Russia and has been investigated for effects on memory, attention, cognitive performance and neurological recovery. Most clinical and experimental research has used Semax intranasally.
One of the main areas of interest is neuroplasticity — the brain’s ability to adapt, form new connections and respond to learning or injury. Semax appears to influence neurotrophic signalling, including pathways involving brain-derived neurotrophic factor (BDNF).
Semax is frequently discussed today as a nootropic or “focus peptide”, but much of its clinical research has actually focused on neurological conditions such as ischemic stroke rather than cognitive enhancement in healthy people.
Semax is not a conventional stimulant. Interest in Semax centres on neurotrophic signalling and brain function rather than directly stimulating the central nervous system in the same way as caffeine or traditional stimulant medications.
Community Discussion
See what the Supp Science community is discussing about Semax.
Semax discussions are on the way
Community threads and discussions about Semax will appear here as they are added to Supp Science.
Independent Testing
Independent laboratory results for Semax commissioned by Supp Science.
Results apply only to the sample tested and may not represent every batch sold by a supplier.
Want Semax independently tested?
Request independent laboratory testing for Semax. Requests are reviewed before testing is commissioned.
No independent tests yet
We don't currently have an independent laboratory result for Semax commissioned by Supp Science. You can request testing and we'll consider it for a future testing round.
Real Experiences
See how Semax performs in the real world, through the experiences of people who have actually used it.
30-Day Semax Review
A structured Supp Science review following one participant's experience with Semax over 30 days, with outcomes documented throughout the review period.
- Focus: Noticeable improvement
- Productivity: Improved
- Memory: Modest improvement
- Sleep: No meaningful change
- Reported issues: Mild nasal irritation
Take Part in a Supp Science Review
Apply to take part in a structured product review. Selected participants receive the product free, with their experience and results documented from start to finish.
Community Experiences
Search real experiences in people's own words.
These are individual user reports collected from third-party sources. They are presented as experiences rather than proof of cause and effect. Use the original-source link to read the surrounding discussion and context.
Semax Research & Evidence
Semax has been studied in humans for cognition and neurological recovery, although much of the clinical research originates from Russia and the overall evidence base remains relatively small.
Memory & Attention
Human research has reported improvements in memory and attention after intranasal Semax, including studies involving healthy people performing under demanding or stressful conditions.
These findings help explain Semax's reputation as a nootropic, although the human evidence is considerably smaller than the research base behind established cognitive medicines.
Brain Network Activity
Brain-imaging research in healthy volunteers has found measurable changes in functional brain connectivity shortly after intranasal Semax.
This supports the idea that Semax can influence brain activity in humans, but changes seen on an fMRI scan do not automatically mean better memory, focus or cognitive performance.
BDNF & Neuroplasticity
Semax has been studied for its effects on neurotrophic signalling, particularly BDNF — a protein involved in supporting neurons and the brain's ability to adapt and form connections.
Human stroke-rehabilitation research has reported increases in plasma BDNF following Semax treatment. However, much of the detailed evidence showing how Semax affects BDNF and related pathways comes from animal research.
Stroke & Neurological Recovery
A significant part of the clinical Semax literature has examined people recovering from ischemic stroke rather than healthy users seeking cognitive enhancement.
Studies have reported improvements in some neurological, motor and functional recovery measures when Semax was added to conventional treatment or rehabilitation.
Neuroprotective Research
Experimental research suggests Semax may influence several processes involved in protecting brain tissue after injury, including neurotrophic signalling and inflammatory responses.
Much of this mechanistic work has been performed in animal or laboratory models, so it should not be interpreted as proof of equivalent neuroprotective effects in healthy humans.
Research Limitations
Semax has more human research than many experimental peptides, but the evidence still has important limitations. Many studies are relatively small, older, published in Russian-language journals or conducted by closely related research groups.
There has been limited independent replication in large modern clinical trials, particularly for the cognitive-enhancement uses most commonly discussed today.
Human studies are available for cognition, brain activity and neurological recovery. The evidence is promising but relatively limited, and many proposed mechanisms are supported more strongly by preclinical research than by large human trials.
Semax Questions & Answers
Semax appears to influence signalling systems involved in brain function, neuroplasticity and the way neurons respond to stress or injury. Research has particularly focused on pathways involving neurotrophic factors such as BDNF.
In human studies, Semax has been investigated for memory, attention and neurological recovery, although its exact effects can vary depending on the population being studied.
No. Semax is not a conventional stimulant like caffeine or amphetamine-based medications.
Some users describe increased alertness or focus, but Semax is primarily studied for its effects on neurotrophic signalling and brain function rather than directly producing conventional central nervous system stimulation.
Research suggests Semax can influence BDNF-related signalling. BDNF is a protein involved in supporting neurons and helping the brain adapt and form or strengthen neural connections.
Increased BDNF has also been reported in human stroke-rehabilitation research, although much of the detailed research explaining how Semax affects this pathway comes from animal and laboratory studies.
Yes. Semax has been studied in humans, including research into memory, attention, brain activity and recovery following ischemic stroke.
The main limitation is that much of the clinical research originates from Russia and has not been replicated through the same volume of large international trials used for widely established medicines.
Focus and cognitive performance are major reasons Semax is discussed in nootropic communities today, but that is only part of its research history.
A significant amount of clinical research has examined Semax in neurological conditions, particularly ischemic stroke and neurological recovery.
Intranasal administration is the route used in much of the published Semax research and in its established medical use in Russia.
It allows the peptide to be administered through the nasal passages rather than requiring conventional oral or injectable delivery.
Ask the Supp Science Team
Can't find what you're looking for? Send us your question and we'll look into it.
Medical Literature
Published human research on Semax, with the key findings summarised in plain English.
A nootropic adrenocorticotropin analogue 4-10-Semax
This paper describes human research in which intranasal Semax was associated with improved memory and attention, including testing in healthy men performing under demanding conditions.
View Study →Semax in acute ischemic stroke
Semax was studied in 30 patients during the acute phase of ischemic stroke and compared with 80 patients receiving conventional therapy. Researchers reported faster recovery of some neurological functions, particularly motor deficits, in the Semax-treated group.
View Study →Semax during rehabilitation after ischemic stroke
In 110 people undergoing stroke rehabilitation, Semax was associated with higher plasma BDNF levels and improvements in functional recovery measures. The study also found a relationship between BDNF levels and functional outcomes.
View Study →Semax has published human research, but much of the clinical literature originates from Russia and includes relatively small or older studies. Findings should be interpreted in the context of the population and study design rather than assumed to apply to healthy users seeking cognitive enhancement.
Contribute to the Evidence
Supp Science is built around independent testing, real discussion and questions from the community. Help us build a better picture of Semax.